Searched for: subject%3A%22Activated%255C%2Bprotein%255C%2Bc%22
(1 - 8 of 8)
document
Kluft, C. (author), Meijer, P. (author), LaGuardia, K.D. (author), Fisher, A.C. (author), TNO Kwaliteit van Leven (author)
Purpose: The aim of this study was to compare effects of the transdermal contraceptive patch, a desogestrel/ethinyl estradiol (EE)-containing, monophasic combination oral contraceptive (COC) and a levonorgestrel/EE-containing, triphasic COC on hemostasis variables. Study Design: This was a randomized, open-label study of 104 young women who...
article 2008
document
Hemelaar, M. (author), van der Mooren, M.J. (author), Rad, M. (author), Kluft, C. (author), Kenemans, P. (author), TNO Kwaliteit van Leven (author)
Objective: To review the effects of non-oral administration of postmenopausal hormone therapy (HT) on risk markers for atherosclerotic and venous thromboembolic disease.Non-oral postmenopausal HT appears not to increase venous thromboembolic risk, whereas the effect on coronary heart disease risk is less clear. Design: Systematic review of...
article 2008
document
Norris, L.A. (author), Brosnan, J. (author), Bonnar, J. (author), Conard, J. (author), Kluft, C. (author), Hellgren, M. (author), TNO Kwaliteit van Leven (author)
Epidemiological studies have shown that hormone therapy (HT) increases the risk of venous thromboembolism in post menopausal women. The mechanism of this increased risk is unknown; however, activation of the haemostatic system is known to contribute to the pathogenesis of venous thromboembolism. In post-menopausal women the estrogen /progestogen...
article 2008
document
Rad, M. (author), Kluft, C. (author), Ménard, J. (author), Burggraaf, J. (author), de Kam, M.L. (author), Meijer, P. (author), Sivin, I. (author), Sitruk-Ware, R.L. (author), TNO Kwaliteit van Leven (author)
Objective: This study aimed to compare the effects on hemostasis variables of a contraceptive vaginal ring with those of an oral contraceptive. Study design: Twenty-three and 22 healthy premenopausal women were randomized to the contraceptive vaginal ring (150 μg Nestorone and 15 μg ethinyl estradiol) or Stediril 30 during 3 cycles. Analysis of...
article 2006
document
Kluft, C. (author), de Maat, M.P.M. (author), Heinemann, L.A.J. (author), Spannagl, M. (author), Schramm, W. (author), Gaubius instituut TNO (author)
Combined oral contraceptives show clear differences in effect on the tissue factor-initiated coagulation test of activated protein C resistance, which is dependent on the presence and dosage of levonorgestrel. Multiphasic levonorgestrol oral contraceptives differ from monophasic contraceptives and resemble third-generation contraceptives. The...
article 1999
document
Kluft, C. (author), Meijer, P. (author), Gram, J. (author), Jespersen, J. (author), Gaubius instituut TNO (author)
article 1999
document
Bots, M.L. (author), van der Bom, J.G. (author), Haverkate, F. (author), Meijer, P. (author), Hofman, A. (author), Grobbee, D.E. (author), Kluft, C. (author), TNO Preventie en Gezondheid (author)
Background and objective. A low activated protein C (APC) response increases the risk of venous thrombosis, and possibly arterial disease. Apart from the factor V Leiden mutation, other factors may determine the level of APC response. In most studies on the association with arterial disease, cardiovascular risk factors were not appropriately...
article 1996
document
de Fouw, N.J. (author), Haverkate, F. (author), Bertina, R.M. (author), Gaubius Instituut TNO (author)
The effect of purified human activated protein C (APC) and protein S on fibrinolysis was studied by using an in vitro blood clot lysis technique. Blood clots were formed from citrated blood (supplemented with 125I-fibrinogen) by adding thrombin and Ca2+-ions; lysis of the clots was achieved by adding tissue-type plasminogen activator. The...
article 1986
Searched for: subject%3A%22Activated%255C%2Bprotein%255C%2Bc%22
(1 - 8 of 8)